The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial

BACKGROUND: Tuberous Sclerosis Complex (TSC) is a genetic disorder characterised by the development of benign tumours secondary to loss of inhibitory regulation of the mTOR (mechanistic Target of Rapamycin) intracellular growth pathway. Metformin inhibits the mTOR pathway. We investigated whether me...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Sam, Mallick, Andrew A, Edwards, Hannah, Cortina-Borja, Mario, Laugharne, Matthew, Likeman, Marcus, O'Callaghan, Finbar J.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910694/
https://www.ncbi.nlm.nih.gov/pubmed/33681737
http://dx.doi.org/10.1016/j.eclinm.2020.100715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910694/
https://www.ncbi.nlm.nih.gov/pubmed/33681737
http://dx.doi.org/10.1016/j.eclinm.2020.100715

Ejemplares similares